2.17BMarket Cap-4.92P/E (TTM)
7.890High7.230Low14.75MVolume7.890Open7.460Pre Close110.81MTurnover5.74%Turnover RatioLossP/E (Static)286.64MShares15.74052wk High4.14P/B1.95BFloat Cap5.60052wk Low--Dividend TTM257.07MShs Float42.810Historical High--Div YieldTTM8.85%Amplitude4.540Historical Low7.513Avg Price1Lot Size
Recursion Pharmaceuticals Stock Forum
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet